Alex Therapeutics partners with pharmaceutical companies to build evidence-based digital companion apps that help patients manage medications, symptoms and mental health challenges. Their platform combines behavioural design and AI-driven insights to improve adherence and clinical outcomes for complex treatment pathways.

The company focuses on launching indication-specific solutions that go beyond reminders, helping patients and caregivers understand relationships between symptoms and treatments. Alex Therapeutics emphasizes clinical validation and measurable behaviour change.

They work directly with pharma partners to deliver customizable, scalable digital health solutions, including Software as a Medical Device (SaMD) products. The team specialises in cancer and rare disease management, where treatment complexity and high mental-health comorbidity create particular challenges for adherence and quality of life.

Alex Therapeutics has published clinical evidence for its digital therapies and collaborates with industry partners (examples shown on the site include Pfizer, Merck and Vicore). For commercial or partnership enquiries they provide a dedicated contact ([email protected]) and maintain a company LinkedIn presence.